Literature DB >> 10755313

A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect.

N J Millenbaugh1, M G Wientjes, J L Au.   

Abstract

PURPOSES: The pharmacodynamics of most drugs follow the empirical relationship, C(n) x T = h, where C is drug concentration, T is exposure time and h is drug exposure constant. The value of n indicates the relative importance of C and T in determining the effect. An n value greater than 1.0 indicates that for two infusions that produce the same C x T, a short infusion that delivers high concentrations over a short duration will produce a greater C(n) x T and therefore a greater effect, compared to a long infusion that delivers lower concentrations. The reverse is true for an n value less than 1.0 and would support the use of a slow infusion. Hence, it is important to determine the n values and whether the n value significantly differs from 1.0. This report describes a three-step method for this purpose.
METHODS: First, we obtained experimental data on the relationship between drug concentration, treatment time and effect, and analyzed the data with a three-dimensional surface response method to obtain the pharmacodynamic model parameters and the magnitude of data variability. The experiments used mitomycin C and two human cancer cell lines, i.e. bladder RT4 and pharynx FaDu cells. The n values obtained from four experiments ranged from 1.04 to 1.16 for FaDu cells and from 1.14 to 1.46 for RT4 cells. The variability in the effect data decreased from 11.9% at 0% effect to 6.14% at 100% effect. Second, these results were used with Monte Carlo simulations to generate 100 concentration-time-effect data sets, which contained randomly and normally distributed data variability comparable to the experimentally observed variability, for each experimentally determined n value. This is analogous to performing 100 experiments under the same experimental conditions. Third, we analyzed the simulated data sets to obtain 100 estimated n values. The frequency with which these estimated n values fell above or below 1.0 indicated the probability that the experimentally determined n value used in the Monte Carlo simulations was truly different from 1.0. We defined this frequency for individual experiments as F(one), and calculated the overall probability for multiple experiments (F(multiple)). A probability of greater than 97.5% (i.e. P < 0.05 for a two-tailed test) was considered statistically significant.
RESULTS: Analysis of the mitomycin C pharmacodynamic data yielded F(one) and F(multiple) of 99% to 100% for FaDu and RT4 cells, indicating that the n values for these cells were significantly higher than 1.0. A comparison of the statistical significance of the n value analyzed by the three-step pharmacodynamic analysis method, a conventional statistical method such as the Student's t-test and nonlinear regression analysis, indicated two advantages for the pharmacodynamic method: fewer experiments were required (theoretically only one experiment with three replicates would be sufficient) and a higher statistical significance of the n value was obtained.
CONCLUSIONS: In summary, the three-step pharmacodynamic study design and analysis method can be used to define the relative importance of drug concentration and treatment time on drug effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755313     DOI: 10.1007/s002800050039

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

Review 2.  The Valley of Death in anticancer drug development: a reassessment.

Authors:  David J Adams
Journal:  Trends Pharmacol Sci       Date:  2012-03-10       Impact factor: 14.819

3.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

4.  Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel.

Authors:  Hua He; Yanguang Cao
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-08-31       Impact factor: 2.745

5.  Label-free isolation of a prostate cancer cell among blood cells and the single-cell measurement of drug accumulation using an integrated microfluidic chip.

Authors:  A Khamenehfar; T V Beischlag; P J Russell; M T P Ling; C Nelson; P C H Li
Journal:  Biomicrofluidics       Date:  2015-11-12       Impact factor: 2.800

6.  Mahonia aquifolium Extracts Promote Doxorubicin Effects against Lung Adenocarcinoma Cells In Vitro.

Authors:  Ana Damjanović; Branka Kolundžija; Ivana Z Matić; Ana Krivokuća; Gordana Zdunić; Katarina Šavikin; Radmila Janković; Jelena Antić Stanković; Tatjana P Stanojković
Journal:  Molecules       Date:  2020-11-10       Impact factor: 4.411

7.  Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo.

Authors:  Bao-an Chen; Bin-bin Lai; Jian Cheng; Guo-hua Xia; Feng Gao; Wen-lin Xu; Jia-hua Ding; Chong Gao; Xin-chen Sun; Cui-rong Xu; Wen-ji Chen; Ning-na Chen; Li-jie Liu; Xiao-mao Li; Xue-mei Wang
Journal:  Int J Nanomedicine       Date:  2009-10-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.